212 results about "Pain chronic" patented technology

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

In the herpes zoster neuralgia chronic detection and AI identification model training method and system, information of a detector is collected, and the information of the detector comprises age, gender and herpes zoster definite diagnosis time; collecting detection information of a detector, wherein the detection information comprises a ratio of IL18 to IL18BP; pain information of the detected person is collected; the pain information of the detector comprises pain intensity and attack frequency; the pain information of the detected person is marked, marked information is obtained, and the marked information comprises acute pain, chronic pain and the risk degree of converting the acute pain into the chronic pain; performing AI training according to the detector information, the detection information and the annotation information, and obtaining a herpes zoster neuropathic pain AI feature data set after the AI training; the herpes zoster neuralgia AI feature data set is used for detecting the possibility that the herpes zoster neuralgia of the testee is converted from acute pain to chronic pain in combination with AI software. And diagnosis and treatment basis information from a brand new perspective is provided for the post-herpes zoster neuralgia.

Systems and techniques are disclosed to adjust programming of an implantable electrical neurostimulation device for treating chronic pain of a human subject, through the use of a dynamic model adapted to identify pain treatment parameters for a human patient and determine a best device operational program to implement the pain treatment parameters to address the chronic pain condition. In an example, the system to adjust programming of the neurostimulation device performs operations that: obtain data related to a state of pain of the human subject; identify pain treatment parameters using a dynamic model adapted to evaluate the pain treatment parameters in the human subject over a time period, based on the data related to the state of pain; and select a neurostimulation program for the neurostimulation device, corresponding to at least a portion of the identified pain treatment parameters.

The invention relates to sterile bispentadol sebacate, a preparation method thereof and medical application of a medicinal preparation containing the sterile bispentadol sebacate. Wherein the particle size D50 of the sterile bis (tapentadol) sebacate is 0.5 to 10 [mu] m. The invention also provides application of the bispentadol sebacate in preparation of various acute and chronic pain medicines, and the bispentadol sebacate has the characteristic of remarkable long-acting effect.

The invention provides a follow-up visit consultation system for chronic pain patients, and relates to the technical field of intelligent medical treatment, and the system comprises a data collection unit which is used for obtaining subjective pain description data, real-time physiological monitoring data and historical diagnosis and treatment data of a patient; the prediction analysis unit is used for performing pain deterioration risk prediction based on the multi-source data and an artificial intelligence model, and outputting a prediction result containing a risk level and individualized pathological features; and the dynamic intervention unit is used for generating dynamic treatment suggestions according to the prediction result, pushing the dynamic treatment suggestions to the doctor and the patient, and receiving execution feedback data of the patient so as to perform closed-loop optimization on the treatment strategy. According to the technical scheme, the subjective pain description, the real-time physiological monitoring data and the historical diagnosis and treatment records of the patient are obtained at the same time, the integrity of the data is improved through the comprehensive collection mode of multi-source data, the accuracy and timeliness of information are ensured, and the problems of subjective deviation and inaccuracy caused by the fact that follow-up visit depends on memory of the patient are solved.

The invention relates to gluconic acid pentazocine benzoate as shown in a formula (I), and a preparation method, a pharmaceutical preparation and medical application thereof. The invention provides application of the compound in preparation of medicines for treating moderate and severe acute and chronic pains, and the compound has the effects of high efficacy and low side effect. # imgabs0 #

The invention discloses a man-machine suitability evaluation method for a mattress, and relates to the field of human engineering health monitoring, and the method comprises the steps: screening testers according to a BMI grading standard, and collecting the height, weight, gender, age, sleep habit and chronic pain medical history basic data of the testers to obtain the BMI values of the testers; inputting the BMI value of the tester into the mattress hardness selection model to obtain the hardness range of the tested mattress, arranging a to-be-tested mattress with selected hardness in a constant-temperature and constant-humidity experimental environment, and enabling the tester to lie on the to-be-tested mattress in sequence at a standard supine position and a standard lateral position. According to the method, the spine stiffness demand curve is predicted in real time through the LSTM neural network, millisecond-level dynamic support adjustment is achieved, the response speed is remarkably increased compared with a traditional method, and spine compensatory bending in sleep can be prevented; and in combination with pressure-blood oxygen coupled IRI index calculation, microcirculation disturbance is accurately warned before tissue injury, and the problem of local ischemia is solved through partition adjustment.

According to the three-dimensional electric field coupling modeling method for analgesia provided by the invention, the propagation process of an electric field in each physiological tissue is accurately simulated by constructing a multi-layer bionic tissue model, so that the accuracy and effect of analgesia treatment are improved; calculating the conductivity and dielectric constant of each layer of tissue, performing numerical simulation on electric field distribution by using a finite element analysis technology, optimizing electrode configuration and electrical stimulation parameters, and ensuring the uniformity and stability of the electric field of a target area; a neurophysiology model is integrated, the conduction law of nerve fiber action potential is dynamically simulated, the stimulation effect of electric field intensity on nerve fibers is quantitatively analyzed, analgesia parameters are further optimized, and accurate control over pain signal transmission is achieved. The problems that in an existing electrical stimulation technology, electric field distribution is not uniform, electrode contact is not stable, and the stimulation effect is difficult to last are effectively solved, wide clinical application prospects are achieved, and an efficient, stable and accurate solution is provided especially in non-invasive treatment of chronic pain.

The invention discloses an intelligent drug delivery pain management bracelet, and relates to the fields of wearable equipment, transdermal drug delivery and biological signal processing. The bracelet is integrated with a multi-mode biosensor which comprises a temperature sensor, a pressure sensor, a heart rate sensor, a blood oxygen sensor and a skin electric response sensor, and physiological data related to pain can be collected in real time. Through an embedded microcontroller and a machine learning algorithm, a pain intensity evaluation model is constructed, and real-time evaluation of the pain state of a patient is realized. Based on the pain intensity and the physiological state of a patient, a drug release strategy is dynamically adjusted through an intelligent algorithm, and drugs are released painlessly and accurately through a micro-needle transdermal drug delivery technology, so that the patient obtains the optimal treatment effect. And the functions of data storage, historical analysis and remote doctor monitoring can be expanded. The hand ring is convenient to operate, comfortable to use and suitable for various pain management scenes such as chronic pain and postoperative pain, and the personalized level of pain treatment and patient compliance are remarkably improved.

1. The name of this design product: Handheld red light therapy device for pain. 2. Purpose of this design product: This design product is used for auxiliary treatment of soft tissue injuries and chronic pain. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

Smart insoles provide comfort and support while analyzing gait, improving posture and alignment, and tracking fitness metrics. Raw data from the smart insoles is fed into normative data algorithms to create a unique user report in real-time. A mobile app associated with the smart insole connects users to caregivers, articles, and personalized exercises. Monitoring of these parameters is used for managing chronic pain and sedentary lifestyle. The smart insole is a smart wearable device with a mobile app to monitor and manage chronic pain, which is an effective strategy in reducing foot pain and increasing physical activity.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

The invention discloses an intelligent temperature control health care patch and a preparation method thereof, and belongs to the technical field of medical instruments. The health care patch comprises a surface layer (a CO2 laser drilling PET film and a fluorosilane coating), a temperature control layer (paraffin / mesoporous silica composite phase change material), a medicine layer (wormwood essential oil-paraffin / sodium alginate microcapsules) and a bonding layer (silicone adhesive / hydrogenated castor oil). Ventilation and sweat prevention are achieved through the laser micropores and the hydrophobic coating, the phase change material composite system provides + / -1.4 DEG C temperature control precision, and the 48-hour medicine volatilization loss rate is only 3.2%. The preparation method adopts vacuum impregnation, low-temperature crosslinking and gradient curing processes, and interlayer bubble-free combination and efficient production are realized. The product has thermal therapy accuracy, medicine long-acting slow release property and skin adaptability, and is suitable for the field of chronic pain and joint nursing.

According to the intelligent green light phototherapy glasses and the intelligent adaptation method thereof, a narrow-band green light LED light source with the central wavelength being 530 + / -5 nm is adopted, and individualized pain management is achieved in combination with heart rate variability, electrodermal response and pupil dynamic monitoring. A multi-source sensor and a micro control panel are arranged in the glasses, physiological data are collected in real time, the illumination intensity, frequency and irradiation mode are dynamically adjusted through an artificial intelligence algorithm, and a closed-loop phototherapy control system is constructed. The device supports Bluetooth / Wi-Fi connection, interacts with a mobile terminal APP, and realizes data recording, curative effect evaluation and remote monitoring. The system has multiple safety mechanisms such as constant-current driving, temperature feedback, over-illumination protection and posture detection, and long-term wearing safety is ensured. Through the regulation effect of green light on pain neural pathways, a safe, portable and intelligent chronic pain non-drug treatment means is provided under the condition that daily activities are not interfered, and high compliance and a remarkable analgesic effect are achieved.

The invention relates to the technical field of electroencephalogram characteristic index calculation, and discloses a chronic pain electroencephalogram index calculation algorithm, which comprises a data preprocessing stage, a multi-layer perceptron architecture design, a model training stage, a model evaluation stage and a multi-scale information fusion stage. The data preprocessing stage further comprises normalization and data division; the architecture design of the multi-layer sensor comprises an input layer, a hidden layer and an output layer; the model training stage comprises a loss function and optimization algorithm, forward propagation, loss calculation, back propagation and parameter updating one-set repeated training; in the model evaluation stage, evaluation needs to be carried out on a test set, and hyper-parameters are adjusted. According to the method, the connection strength or the activity level of different regions of the brain under different threshold values is reflected, the association between the brain nerve activity and the chronic pain can be described more comprehensively by fusing the connection strength or the activity level, the pain related mode hidden in the association can be mined, the limitation of single feature analysis is avoided, and comprehensive evaluation of the chronic pain is facilitated.

The invention provides a nano-drug carrier and a drug release system, the nano-drug carrier comprises a drug loading core and a responsive shell arranged outside the drug loading core, and the drug loading core is loaded with a nano-drug; the surface of the responsive shell is modified with a targeting ligand, and the targeting ligand can specifically target pain-related cells or tissues. According to the nano-drug carrier and the drug release system provided by the invention, precise long-acting treatment of chronic pain is realized through combination of an environment-responsive carrier and an active targeting technology. The technology can significantly improve local accumulation of the medicine and reduce systemic toxicity, and is suitable for management of intractable pains such as neuropathic pains and osteoarthritis.

Presented herein are devices and systems as well as the methods of using the same for the purpose of reducing and / or ameliorating the sensation of pain, specifically, chronic pain. Particularly, in one aspect, the devices, systems, and their methods of use disclosed herein are effective for reducing peripheral nerve pain, such as resulting from traumatic nerve injury and other types of nerve damage.

Methods and compositions are provided for treating an individual in need (e.g., one who has chronic pain). Such methods can include a step of administering a therapy that reduces CamKv activity in opioid receptor mu 1 (OPRM1) expressing neurons of the individual's rostral ventromedial medulla (RVM). In some cases, the therapy (e.g., deep brain stimulation of zona incerta neurons) increases inhibitory input into the individual's RVM. In some cases, the therapy is an agent (e.g., an RNAi agent) that reduces expression or activity of CamKv in the individual's RVM. In some cases, the agent includes a retrograde-enhanced recombinant AAV particle, e.g., one that can be used to deliver an RNAi agent such as an shRNA that targets CamKv. Also provide are retrograde-enhanced clade E variant AAV capsid proteins, AVV particles that include such capsid proteins, methods of making such AAV particles, and methods of expressing a transgene using such AAVs.

The invention discloses a pain dynamic monitoring and early warning system based on a biosensor. The pain dynamic monitoring and early warning system comprises a sensor layer, a signal processing layer, a data transmission layer and a data analysis and early warning layer. The sensor layer collects multi-mode biological signals related to pain, and the signal processing layer carries out filtering, amplification and analog-to-digital conversion on the collected signals, eliminates noise and extracts effective information. The data transmission layer transmits processed data to a mobile device or a cloud platform by using a wireless communication technology, and the data analysis and early warning layer performs deep analysis on the data by using an improved convolutional neural network and a long-short-term memory network, establishes a pain model, evaluates the pain degree in real time, and sends out an early warning signal according to a dynamically set early warning threshold value, so as to realize early warning. And medical workers are reminded to take corresponding measures. According to the invention, objective, real-time and accurate pain monitoring and early warning can be realized, an intelligent solution is provided for pain management, and the system is especially suitable for post-operation pain monitoring, chronic pain management and other scenes.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

The invention provides a preparation method and application of graphene pain-relieving health-care paste, and the method comprises the following steps: mixing carrageenan with water to obtain a carrageenan solution, and carrying out ionization degradation on the carrageenan solution to obtain a carrageenan oligosaccharide solution; the preparation method comprises the following steps: stirring graphene oxide and a carrageenan oligosaccharide solution, cleaning to obtain a mixed solution, adding sodium alginate into the mixed solution to prepare a gel precursor, and adding an anhydrous calcium chloride solution and effective components into the gel precursor to obtain the pain-relieving gel, and drying the gel to obtain the health-care paste. The health-care ointment has the effects of promoting blood circulation, activating collaterals and inhibiting inflammation, and is suitable for various chronic pains such as rheumatic arthritis and lumbar muscle degeneration and acute pains such as traumatic injury and muscle strain; the composition is also suitable for auxiliary relieving of postoperative pain, and has safety and long-term effect. Due to the thermal conductivity of the graphene oxide in the health-care cream, local skin blood circulation can be accelerated, the permeation efficiency of the herbal extract is improved, and the medicine effect of the effective components is improved.

The present invention relates to compounds, compositions and methods for deinhibiting a RE1 silencing transcription factor (REST) target gene. In particular, disclosed is a peptide having the sequences TEDLEPPEPPLPKEN (SEQ ID NO: 1) and EDLEPPEPPLPK (SEQ ID NO: 15) or a reverse sequence (reverse inversion, RI) consisting of D-amino acids nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), for use in the inhibition of REST activity. The peptides can be used for treating, preventing or alleviating diseases such as traumatic brain injury, epilepsy, dementia, Huntington's disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer, diabetes and peripheral nerve injury.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

Systems and methods of applying electrical stimulation to achieve sustained relief of chronic pain that comprise a coiled wire percutaneous lead configured for insertion into a portion of a body that is proximal to a region of pain and an electrode formed integrally on the coiled wire percutaneous lead, wherein the electrode is configured to be positioned inside the body and at a therapeutically effective distance from a portion of at least one peripheral nerve that innervates the region of pain. The systems and method may also include an electrical stimulation device operatively coupled to the lead to apply electrical stimulation through the at least one electrode to at least one peripheral nerve that innervates the region of pain, to activate target peripheral nerve fibers while preventing activation of non-target peripheral nerve fibers and avoiding changing or blocking neural activity in off-target peripheral nerve fibers in the at least one peripheral nerve to create comfortable sensations in the region of pain and produce pain relief by modulating central nervous system plasticity associated with the pain.

The invention relates to the field of guidance information recommendation, in particular to an AR-based chronic pain relieving guidance system and method, and the method comprises the steps: carrying out the continuous monitoring of each feedback monitoring parameter, and determining whether to carry out the optimization screening analysis or not according to a reference feedback evaluation index; determining execution association analysis or execution trend analysis according to the execution evaluation difference index and the execution evaluation trend index; when the correlation analysis is executed, determining parameters on which priority guidance information is selected according to the stage execution part parameters and the set evaluation difference index; when the execution trend analysis is carried out, determining whether optimization guidance information is determined or not according to the execution trend difference index; and when the optimal guidance information is determined, updating and replacing the pain relieving guidance scheme based on the determined optimal guidance information. According to the invention, the matching degree of the related medical record information of the patient is improved, so that the adaptation degree of the recommended guidance scheme is improved.

The present invention relates to an N-benzyl phthalimide derivative compound of formula I, a pharmaceutical composition comprising the same, a medicament, its use, combination, and methods for treating acute and chronic pain, primarily focusing on neuropathic disorders and syndromes associated with neuropathic pain.

The invention discloses a closed-loop analgesia method and system for regulating and controlling a secondary sensory cortex based on primary sensory cortex neural activity feedback. The system comprises a signal acquisition module used for acquiring neuron activity signals in the S1 region, a pain judgment module used for analyzing the signals and judging the pain state, a feedback control module used for generating stimulation control signals, and a stimulation execution module used for applying adjustable nerve regulation stimulation to the S2 region. According to the method, a specific pain nerve signal of S1 is monitored in real time and serves as a closed-loop feedback source, intervention on S2 is dynamically controlled, stimulation parameters are automatically started and optimized only when pain is detected, stimulation is automatically weakened or stopped after the pain fades away, and therefore self-adaptive, on-demand and accurate intelligent analgesia is achieved. According to the invention, accurate pain determination is realized by using a specific signal at the upstream of a pain pathway, personalized, efficient and low-energy-consumption intelligent analgesia is realized through closed-loop control, and a brand new solution is provided for chronic pain treatment.